All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Apalutamide Plus ADT Improves PSA-PFS in High-Risk Biochemically Relapsed Prostate Cancer

February 9th 2024

Apalutamide plus androgen deprivation therapy improved prostate-specific antigen progression-free survival in castration-sensitive prostate cancer.

European Approval Sought for Frontline Amivantamab Plus Lazertinib in EGFR+ NSCLC

February 9th 2024

The EMA is evaluating a Type II extension of indication application for the approval of first-line amivantamab plus lazertinib in EGFR-mutated NSCLC.

Florida’s Largest, Long-Standing Community Oncology Practice Establishes Management Services Organization

February 9th 2024

Florida Cancer Specialists & Research Institute announces their intentions to explore a new distributor and group purchasing organization partnerships.

Phase 3 Randomized Trials: Expanding Clinically Meaningful Analysis Beyond the Stated Goals

February 9th 2024

The foundation of physician recommendations and medical/regulatory policy will be guided by the outcomes of published clinical research.

European Commission Grants Orphan Drug Designation to NXC-201 for AL Amyloidosis

February 8th 2024

NXC-201 has received orphan drug designation from the European Commission for use in patients with amyloid light-chain amyloidosis.

Gilead Discontinues Phase 3 ENHANCE-3 Trial of Magrolimab Plus Venetoclax/Azacitidine in AML

February 8th 2024

The phase 3 ENHANCE-3 study of magrolimab plus venetoclax/azacitidine vs venetoclax/azacitidine in select patients with AML has been terminated.

Complementary NGS Improves dMMR Detection With IHC in CRC and Endometrial Cancer

February 8th 2024

Amin Nassar, MD, and Elias Bou Farhat, MD, spotlight a study evaluating the accuracy and sensitivity of NGS mutation signature in assessing MMR status vs IHC testing.

Retrospective Review Sheds Light on Real-World Efficacy With Teclistamab in R/R Myeloma After BCMA-Directed Therapy

February 8th 2024

Teclistamab produced responses in real-world patients with relapsed and refractory multiple myeloma and prior exposure to BCMA-targeted therapy.

Tulane Doctors Extend Their Reach in 2024

February 8th 2024

The Tulane Transplant Institute offers comprehensive disease management for patients with end-stage organ disease of the kidney, liver, and pancreas.

HPN328 Shows Clinical Activity and Tolerability in Neuroendocrine Prostate Cancer

February 8th 2024

HPN328, was well tolerated and elicited responses in patients with neuroendocrine prostate cancer and other neuroendocrine neoplasms.

Dhruva Details How Physicians Can Learn More About the FDA Approval Process

February 8th 2024

Dhruva explains how physicians reported a lack of understanding when it comes to the FDA approval process, especially regarding expedited approval pathways.

HIPEC Plus Surgery Prolongs PFS and OS in Stage III Ovarian Cancer

February 8th 2024

Hyperthermic intraperitoneal chemotherapy plus interval cytoreductive surgery improved progression-free survival in stage III epithelial ovarian cancer.

Goserelin Included in Latest NCCN Breast Cancer Guidelines

February 7th 2024

The NCCN Breast Cancer Panel has included goserelin at 2 dosing schedules as a method for ovarian function suppression in their updated guidelines.

Continued ADC Development in NSCLC Necessitates Improved Knowledge of Mechanisms and Biomarker Optimization

February 7th 2024

Identifying biomarkers and the mechanism of action of antibody-drug conjugates may optimize benefits with these agents in non–small cell lung cancer.

Neoadjuvant vs Perioperative Immune Checkpoint Blockade in Resectable NSCLC: How Do We Choose?

February 7th 2024

Survival outcomes following curative resection in resectable NSCLC have been poor and, until recently, the main tool oncologists had at their disposal was neoadjuvant or adjuvant chemotherapy.

EGFR TKI–Based Combinations May Revolutionize Frontline EGFR+ NSCLC Management

February 7th 2024

Balazs Halmos, MD, discusses the FLAURA2 and MARIPOSA trials of EGFR TKIs plus chemotherapy in EGFR-mutated non–small cell lung cancer.

Single-port Robotic Surgery Is Making Its Debut In The Mountain West

February 7th 2024

Huntsman Cancer Institute introduces the first and only single-port robot in the Mountain West for head and neck surgical oncology patients.

Regulatory Filings Accepted for Perioperative Nivolumab Plus Chemotherapy in NSCLC

February 7th 2024

The FDA and EMA have accepted applications seeking the approval of neoadjuvant nivolumab/chemotherapy followed by surgery and adjuvant nivolumab in NSCLC.

2023 Data Readouts Enable New Treatment Avenues in Oncogene-Driven NSCLC

February 7th 2024

Edgardo S. Santos Castillero, MD, FACP, spotlights some impactful trials in lung cancer that were discussed in 2023, including the phase 3 MARIPOSA-2 trial, and more.

Early-Phase Clinical Research Center Poised to Provide New Benefits in Hawaii and Beyond

February 7th 2024

The University of Hawaii Cancer Center hopes to address treatment needs through its planned Early Phase Clinical Research Center.